当前位置: 首页 >> 检索结果
221. Guidelines Development Group for the British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma.
作者: Shahid A Khan.;Simon M Rushbrook.;Timothy James Kendall.;Yoh Zen.;Raneem Albazaz.;Prakash Manoharan.;Stephen P Pereira.;Richard Sturgess.;Brian R Davidson.;Hassan Z Malik.;Derek Manas.;Nigel Heaton.;K Raj Prasad.;Juan W Valle.;Rebecca Goody.;Maria Hawkins.;Wendy Prentice.;Helen Morement.;Martine Walmsley.;John Bridgewater.
来源: Gut. 2025年74卷3期504-505页 223. Clinical outcomes of potential coeliac disease: a systematic review and meta-analysis.
作者: Mohamed G Shiha.;Annalisa Schiepatti.;Stiliano Maimaris.;NIcoletta Nandi.;Hugo A Penny.;David S Sanders.
来源: Gut. 2024年73卷12期1944-1952页
Potential coeliac disease (PCD) is characterised by positive serological and genetic markers of coeliac disease with architecturally preserved duodenal mucosa. The clinical outcomes and rates of progression to overt coeliac disease in patients with PCD remain uncertain. In this systematic review and meta-analysis, we aimed to evaluate the clinical outcomes of patients with PCD.
225. External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab.
作者: Nicolas Pierre.;Vân Anh Huynh-Thu.;Dominique Baiwir.;Gabriel Mazzucchelli.;Maximilien Fléron.;Lisette Trzpiot.;Gauthier Eppe.;Edwin De Pauw.;David Laharie.;Jack Satsangi.;Peter Bossuyt.;Lucine Vuitton.;Sophie Vieujean.;Jean-Frédéric Colombel.;Marie-Alice Meuwis.;Edouard Louis.; .
来源: Gut. 2024年73卷12期1965-1973页
In patients with Crohn's disease (CD) on combination therapy (infliximab and immunosuppressant) and stopping infliximab (cohort from the study of infliximab diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunosuppressors (STORI)), the risk of short-term (≤6 months) and mid/long-term relapse (>6 months) was associated with distinct blood protein profiles. Our aim was to test the external validity of this finding in the SPARE cohort (A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy).
226. The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines.
作者: Mario Dinis-Ribeiro.;Shailja Shah.;Hashem El-Serag.;Matthew Banks.;Noriya Uedo.;Hisao Tajiri.;Luiz Gonzaga Coelho.;Diogo Libanio.;Edith Lahner.;Antonio Rollan.;Jing-Yuan Fang.;Leticia Moreira.;Jan Bornschein.;Peter Malfertheiner.;Ernst J Kuipers.;Emad M El-Omar.
来源: Gut. 2024年73卷10期1607-1617页
During the last decade, the management of gastric intestinal metaplasia (GIM) has been addressed by several distinct international evidence-based guidelines. In this review, we aimed to synthesise these guidelines and provide clinicians with a global perspective of the current recommendations for managing patients with GIM, as well as highlight evidence gaps that need to be addressed with future research.
227. Environmental impact of single-use versus reusable gastroscopes.
作者: Mathieu Pioche.;Heiko Pohl.;João A Cunha Neves.;Arthur Laporte.;Mikael Mochet.;Jérôme Rivory.;Raphaelle Grau.;Jérémie Jacques.;Daniel Grinberg.;Mathilde Boube.;Robin Baddeley.;Pierre-Jean Cottinet.;Marion Schaefer.;Enrique Rodríguez de Santiago.;Arthur Berger.; .
来源: Gut. 2024年73卷11期1816-1822页
The environmental impact of endoscopy is a topic of growing interest. This study aimed to compare the carbon footprint of performing an esogastroduodenoscopy (EGD) with a reusable (RU) or with a single-use (SU) disposable gastroscope.
228. Direct toll-like receptor triggering in colorectal cancer-associated stromal cells elicits immunostimulatory properties leading to enhanced immune cell recruitment.
作者: Julija Djordjevic.;Nubia Sarahi Cisneros Romero.;Luciano Cascione.;Valentina Mele.;Eleonora Cremonesi.;Elisa Sorrenti.;Camilla Basso.;Martina Villa.;Agnese Cianfarani.;Raffaello Roesel.;Jacopo Galafassi.;Pietro Edoardo Majno-Hurst.;Giulio Spagnoli.;Dimitrios Christoforidis.;Giandomenica Iezzi.
来源: Gut. 2025年74卷2期333-335页 229. Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease families.
作者: Jonathan P Jacobs.;Elizabeth A Spencer.;Drew S Helmus.;Julianne C Yang.;Venu Lagishetty.;Gerold Bongers.;Graham Britton.;Kyle Gettler.;Pamela Reyes-Mercedes.;Jianzhong Hu.;Amy Hart.;Esi Lamousé-Smith.;Jan Wehkamp.;Carol Landers.;Philip Debbas.;Joana Torres.;Jean-Frederic Colombel.;Judy Cho.;Inga Peter.;Jeremiah Faith.;Jonathan Braun.;Marla Dubinsky.
来源: Gut. 2024年73卷12期1953-1964页
IBD is characterised by dysbiosis, but it remains unclear to what extent dysbiosis develops in unaffected at-risk individuals. To address this, we investigated age-related patterns of faecal and serum markers of dysbiosis in high-risk multiplex IBD families (two or more affected first-degree relatives).
230. Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
作者: Xianhua Mao.;Xinrong Zhang.;Leslie Kam.;Nicholas Chien.;Rongtao Lai.;Ka-Shing Cheung.;Man-Fung Yuen.;Ramsey Cheung.;Wai-Kay Seto.;Mindie H Nguyen.
来源: Gut. 2024年73卷12期2054-2061页
Type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease (diabetic MASLD) frequently coexist and worsen liver and non-liver outcomes, but effective pharmacological therapies are limited. We aimed to evaluate the long-term effect of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) on liver and non-liver outcomes among patients with diabetic MASLD.
231. Animal experiments of a new through-the-scope full-thickness endoscopic suturing device.
作者: Mati Shnell.;Erez Scapa.;Maria Valeria Matteo.;Hideyuki Chiba.;Yohei Minato.;Leon M G Moons.;Vincenzo Bove.;Shelby Sullivan.;Ken Ohata.;Ivo Boskoski.
来源: Gut. 2024年73卷12期1931-1933页 232. Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA.
作者: Alexander H Yang.;Monica A Tincopa.;Federica Tavaglione.;Veeral H Ajmera.;Lisa M Richards.;Maral Amangurbanova.;Christian Butcher.;Christie Hernandez.;Egbert Madamba.;Seema Singh.;Ricki Bettencourt.;Bernd Schnabl.;Claude B Sirlin.;Rohit Loomba.
来源: Gut. 2024年73卷12期2045-2053页
There are limited prospective data among overweight and obese individuals on the prevalence of advanced fibrosis, and cirrhosis using advanced MRI-based methods in the USA. The aim of this study was to fill that gap in knowledge by prospectively determining the MRI-based prevalence of steatotic liver disease (SLD) and its subcategories, advanced fibrosis and cirrhosis among overweight and obese individuals residing in the USA.
233. Endocytoscopy with automated multispectral intestinal barrier pathology imaging for assessment of deep healing to predict outcomes in ulcerative colitis.
作者: Snehali Majumder.;Giovanni Santacroce.;Yasuharu Maeda.;Irene Zammarchi.;Miguel Puga-Tejada.;Ilaria Ditonno.;Brian Hayes.;Rory Crotty.;Eanna Fennell.;Uday N Shivaji.;Zainab Abdawn.;Rahul Hejmadi.;Tommaso Lorenzo Parigi.;Olga Maria Nardone.;Paul Murray.;Louise Burke.;Subrata Ghosh.;Marietta Iacucci.
来源: Gut. 2024年73卷10期1603-1606页 234. Submucosal steroid pre-injection strategy to prevent oesophageal stricture after circumferential endoscopic submucosal dissection.
作者: Ke Zhan.;Pengfei Wang.;Wei-Hui Liu.;Yang Bai.;Daorong Chen.;Ling Sun.;Min Qiao.;Jianhua Dai.;Xusheng Nie.;Xin Yang.
来源: Gut. 2024年73卷11期1780-1784页 235. Dynamics of the gut microbiome in FAP patients undergoing intensive endoscopic reduction of polyp burden.
作者: Sayaka Mizutani.;Ayako Tamaki.;Satoshi Shiba.;Felix Salim.;Masayoshi Yamada.;Hiroyuki Takamaru.;Takeshi Nakajima.;Naohisa Yoshida.;Shoko Ikuta.;Tatsuo Yachida.;Tatsuhiro Shibata.;Tomoyoshi Soga.;Yutaka Saito.;Shinji Fukuda.;Hideki Ishikawa.;Takuji Yamada.;Shinichi Yachida.
来源: Gut. 2025年74卷2期335-338页 237. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease.
作者: Xiao-Dong Zhou.;Seung Up Kim.;Terry Cheuk-Fung Yip.;Salvatore Petta.;Atsushi Nakajima.;Emmanuel Tsochatzis.;Jérôme Boursier.;Elisabetta Bugianesi.;Hannes Hagström.;Wah Kheong Chan.;Manuel Romero-Gomez.;José Luis Calleja.;Victor de Lédinghen.;Laurent Castéra.;Arun J Sanyal.;George Boon-Bee Goh.;Philip N Newsome.;Jiangao Fan.;Michelle Lai.;Céline Fournier-Poizat.;Hye Won Lee.;Grace Lai-Hung Wong.;Angelo Armandi.;Ying Shang.;Grazia Pennisi.;Elba Llop.;Masato Yoneda.;Marc de Saint-Loup.;Clemence M Canivet.;Carmen Lara-Romero.;Rocio Gallego-Duràn.;Amon Asgharpour.;Kevin Kim-Jun Teh.;Sara Mahgoub.;Mandy Sau-Wai Chan.;Huapeng Lin.;Wen-Yue Liu.;Giovanni Targher.;Christopher D Byrne.;Vincent Wai-Sun Wong.;Ming-Hua Zheng.; .
来源: Gut. 2024年73卷11期1883-1892页
Statins have multiple benefits in patients with metabolic-associated steatotic liver disease (MASLD).
239. Association of breast milk-derived arachidonic acid-induced infant gut dysbiosis with the onset of atopic dermatitis.
作者: Suhua Jiang.;Mengyun Cai.;Dingru Li.;Xiangping Chen.;Xiaoqian Chen.;Qitao Huang.;Caimei Zhong.;Xiufeng Zheng.;Dan Zhou.;Zhiyan Chen.;Lin Zhang.;Jessica Yl Ching.;Ailing Chen.;Shaoxia Lu.;Lifang Zhang.;Ling Hu.;Yan Liao.;Ying Li.;Zhihua He.;Jingjing Wu.;Huiyi Huo.;Yongqi Liang.;Wanwen Li.;Yanli Zou.;Wei Luo.;Siew C Ng.;Francis Kl Chan.;Xia Chen.;Yuhua Deng.
来源: Gut. 2024年74卷1期45-57页
The specific breast milk-derived metabolites that mediate host-microbiota interactions and contribute to the onset of atopic dermatitis (AD) remain unknown and require further investigation.
240. Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'.
作者: Harsh Vardhan Tevethia.;Apurva Pande.;Rajan Vijayaraghavan.;Guresh Kumar.;Shiv Kumar Sarin.
来源: Gut. 2024年73卷11期1844-1853页
Beta-blockers and endoscopic variceal band ligation (VBL) have been preferred therapies for primary prophylaxis of variceal bleeding. However, the choice of therapy in patients with advanced liver disease with high-risk varices is not clear. A comparison of these therapies alone or in combination to prevent the first variceal bleed in advanced cirrhosis patients was carried out.
|